tbuckley/cabot-search huggingface dataset:
SP0079 Illness Beliefs as A Treatment Target in Chronic Pain
Authors: M.P. Jensen
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> Psychosocial models of chronic pain argue for a causal role for pain beliefs in the development and maintenance of chronic pain. A great deal of evidence supports an association between pain beliefs – in particular beliefs regarding (a) the meaning of pain with respect to bodily damage, (b) the extent to which one is disabled by pain, (c) one9s sense of control over pain, and (d) catastrophizing beliefs – and important pain treatment outcomes. Thus, both theory and research support the possibility that pain-related beliefs may be viable treatment targets in individuals with chronic pain. A preliminary study comparing the effects of a cognitive restructuring intervention (targeting <i>only</i> pain-related beliefs, and not behavior or coping), relative to an education control condition, supports the causal impact of beliefs on pain intensity. A follow-up study comparing the effects of (a) a cognitive restructuring intervention targeting pain beliefs, (b) a self-hypnosis training condition targeting pain intensity, and (c) a hypnotic cognitive therapy intervention targeting pain beliefs, relative to an education control condition, provide additional support for the specific effects of cognitive restructuring on pain intensity. As a group, this research supports the viability of pain beliefs as treatment targets, cognitive restructuring as an effective strategy for impacting pain by altering pain beliefs, and the potential of using hypnosis to enhance the efficacy of cognitive therapy. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6180
Recurrent Infections, Episodic Lymphopenia and Impaired Cellular Immunity
Authors: R. Kretschmer, C. S. August, F. S. Rosen, C. A. Janeway
Journal: New England Journal of Medicine (1969)

Two siblings, a boy and a girl, died in childhood with an illness characterized by recurrent infections, eczema and episodes of lymphopenia. Post-mortem examinations in both showed depletion of small lymphocytes from thymus-dependent areas of peripheral lymphoid organs. Immunologic studies carried out in the boy revealed dysgammaglobulinemia, impaired cellular immunity, and absent immunologic memory. By means of a 51Cr-release assay, it was possible to demonstrate the presence of a complement-dependent, lymphocytotoxic factor in the boy's serum during an episode of lymphopenia. It is suggested that these patients with "immunologic amnesia" resemble laboratory animals treated with antilymphocyte serum.
Digital Mucous Cyst
Authors: Gabriel Salerni, Carlos Alonso
Journal: New England Journal of Medicine (2012)

A 37-year-old man presented with a history of a solitary, round, asymptomatic nodule on his second toe. The nodule measured 6 mm in diameter and was located off the midline on the dorsal side of the second toe, between the interphalangeal joint and the proximal nail fold.
FRI0041 Synovial lymphoid neogenesis in rheumatoid arthritis is associated with higher expression of TH17/23 cytokine axis and higher disease activity
Authors: J.D. Cañete, R. Celis, J. Ramírez, S. Marsal, O.M.O. Epis, V. Ruiz-Esquide, G. Avila, R. Sanmarti, J.L. Pablos
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Accumulation of B cells in synovial lymphoneogenesis (LN) structures could drive antibody-independent synovial inflammation through the development of specific T cell responses or by enhancing cytokine production. This might result in differences in the disease phenotype between patients with and without synovial LN, which might have prognostic interest. <h3>Objectives</h3> We analyzed whether synovial lymphoid neogenesis (LN) in rheumatoid arthritis (RA) is associated with specific patterns of inflammatory cytokine expression in synovial tissue (ST) and Synovial fluid (SF), and the potential association of cytokine expression with disease activity and response to therapy. <h3>Methods</h3> Paired ST (n=63) and SF (n=44) samples were obtained by arthroscopy from the inflamed knee of RA patients. A second ST sample was obtained after a mean of 8±5 months of treatment in 21 patients who started therapy with TNF-alpha antagonists. ST samples were immunostained for CD3 (T cell), CD20 (B cell), and MECA-79 epitope (high endothelial vessels). Total ST mRNA was extracted and gene expression of CCR7, LT-beta, IL-7, IL-10, IL-17A, IL-21, IL-22, IL-23, TNF-alpha, IL-1b, and IL-6 was measured by quantitative real-time PCR. SF concentration of Th1, Th2, Th17 and proinflammatory cytokines was determined by Quantibody® Human Th17 Array. Clinical and biological data were collected at inclusion and after a median follow-up of 2.4 years. <h3>Results</h3> Thirty out of 63 patients (47.6%) had LN, which was associated with a significantly higher expression of ST CCR7 (p=0.009), IL-21 (p=0.009) and IL-23 (p=0.016). LN-positive patients also had significantly higher SF levels of IL-23 (p=0.018) and IL-17F (p=0.028). SF levels of IFN-gamma, TGF-beta1 and IL-21 were higher in LN-positive patients, but the difference did not reached statistical significance. LN-positive patients had significantly higher DAS28 at inclusion (p=0.039). In the group of patients sequentially biopsied before and after anti-TNF-alpha blocker therapy, EULAR good response was only associated with a decrease on IL-10 mRNA expression (p=0.035). <h3>Conclusions</h3> RA patients with histological LN exhibit higher expression of Th17/23 related cytokines and higher disease activity as compared to LN-negative patients. Only reduction in IL-10 mRNA expression after anti-TNF-alpha therapy was associated with a better EULAR response. <h3>Disclosure of Interest</h3> None Declared
AB0934 Higher disease activity and earlier arthritis onset are associated with risk of coronary heart disease development in patients with psoriatic arthritis:
Authors: I. Gaydukova, A. Rebrov, D. Poddubnyy
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Psoriatic arthritis (PsA) is characterized by increased cardiovascular morbidity and mortality [1]. However, data about clinical features of PsA related to adverse cardiovascular events in this population are limited. <h3>Objectives</h3> The aim of the study was to evaluate disease related factors associated with coronary heart disease’s (CHD) manifestation in patients with PsA. <h3>Methods</h3> 52 patients with PsA according to CASPAR criteria without clinical features of cardiovascular diseases were involved in the study. Screening for cardiovascular risk factors and cardiovascular disease was performed at baseline and after 6 to 12 month of observation. PsA activity assessment was performed by standard procedures (disease activity score (DAS), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)). <h3>Results</h3> After 6 to 12 month of observation a new onset CHD was recorded in 15 patients (angina pectoris in 10 patients, atrial fibrillation in 2 patients, myocardial infarction in 2 patients and sudden cardiac death in one man). Conventional cardiovascular risk factors (higher age, higher arterial blood pressure, and higher body mass index – BMI) were clearly associated with a CHD development. After matching for conventional cardiovascular risk factors, the following parameters were found to be associated with a new onset CHD: higher disease activity, earlier arthritis onset, and longer disease duration (table 1). <h3>Conclusions</h3> Higher activity of PsA, earlier disease onset and, consequently, longer disease duration associates with an exceeded risk of CHD in PsA patients independently from convectional cardiovascular risk factors. <h3>References</h3> Gladman DD, et al. Arthritis Rheum 1998;41:1103-10. <h3>Disclosure of Interest</h3> None Declared
Abstract 435: Reduction of the invasive phenotype of SNAI overexpressing human breast cancer cells by peptide aptamer-mediated inhibition of SNAI protein functions
Authors: Charvann K. Bailey, Mukul K. Mittal, Smita Misra, Gautam Chaudhuri
Journal: Cancer Research (2010)

Abstract Two members of the SNAI superfamily of zinc-finger transcriptional repressors: SNAI1 (also known as SNAIL) and SNAI2 (also known as SLUG) are implicated in the induction of aggressiveness and metastatic phenotypes in human breast cancer cells. SNAI1 and SNAI2 are very similar in their amino acid sequences at the C-terminal zinc-finger domains, but the N-terminal repressor domain is somewhat different. SNAI2 has two essential sub-domains, SNAG and SLUG domains, required for its repressor activity. The SNAG domain is also important in SNAI1. We have developed a recombinant protein containing thioredoxin, a tri-repeat of SNAG and SLUG domains of SNAI2 and a membrane translocation motif (MTM; AAVLLPVLLAAP) for the protein to be targeted to the nucleus. We expressed and purified this protein from E. coli using the His-patch thiofusion expression system (Invitrogen). When delivered to MDA-MB-231 and BT549 cells, this aptamer inhibited the functions of the SNAI proteins. The effect of SNAI protein knockdown by the peptide aptamer on the transformed phenotypes of these cells was evaluated by investigating the following parameters: (i) Measurement of doubling time and saturation density by plating cells and performing daily counts. (ii) Evaluation of cellular proliferation by measuring incorporation of 5′-bromodeoxyuridine into logarithmically growing cells. (iii) Determination of anchorage-independent growth in soft agar assays and analysis of the number and size of colonies formed. (iv) Evaluation of the cellular migration in scratch assays and in modified Boyden Chamber/transwell migration assays (directional migration). (v) Measurement of cellular invasion in vitro by using Matrigel-coated chambers. (vi) Assessment of the sensitivity to anoikis by plating cells on poly-HEMA coated plates and determination of cells undergoing apoptosis with propidium iodine staining or annexin labeling and flow cytometric analysis. (vii) Performing 3D culture assays to analyze invasiveness, proliferation or matrix degradation. All these data indicated reduction of the invasive phenotypes of the SNAI protein over expressing highly aggressive and metastatic human breast cancer cells by the peptide aptamer. Wrapsome-mediated targeted delivery of this aptamer alone or with other drugs may be used to reduce the progression of breast cancer. Supported by the DOD-CDMRP IDEA Grant# W81XWH-06-1-0466 and the Susan G. Komen Breast Cancer Foundation grant# BCTR0707627 to GC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 435.
IMPAIRED BASELINE GLOBAL CIRCUMFERENTIAL STRAIN IS A MARKER FOR VENTRICULAR ARRHYTHMIAS AFTER RESYNCHRONIZATION THERAPY IN PATIENTS WITH ISCHEMIC CARDIOMYOPATHY
Authors: Antonia Delgado-Montero, Bhupendar Tayal, Akiko Goda, Stephanie Holt, David Schwartzman, Samir Saba, John Gorcsan
Journal: Journal of the American College of Cardiology (2015)
Significance of the<i>Staphylococcus aureus</i>Carrier State in the Treatment of Disease Due to Group A Streptococci
Authors: Ruth B. Kundsin, Joseph M. Miller
Journal: New England Journal of Medicine (1964)

THE therapeutic objective in infection due to Group A streptococci is the eradication of the organism from the respiratory tract to prevent the chain of events leading to rheumatic fever. Despite the in vitro susceptibility of all strains of Group A streptococci to penicillin, treatment failures continue to occur as judged by the persistence of streptococci after presumably effective doses of penicillin.Consideration of reasons for treatment failures is varied. In one study, interest has focused on patient co-operation in taking the therapeutic agent for the fully prescribed period.1 Other investigators have observed the persistence of penicillin-susceptible organisms after penicillin . . .
Increased 18F-FDG Uptake on PET/CT is Associated With Poor Arterial and Portal Perfusion on Multiphase CT
Authors: Sang Hyun Hwang, Minwook Lee, Narae Lee, Saewhan Park, Chun Ki Kim, Mi-Ae Park, Mijin Yun
Journal: Clinical Nuclear Medicine (2016)

To correlate 18F-FDG uptake on PET/CT with patterns of arterial and portal perfusion on multi-detector CT (MDCT) in patients with hepatocellular carcinoma (HCC) and to assess the value of variables from PET/CT and MDCT in predicting histological grades and overall survival.We retrospectively analyzed MDCT and PET/CT of 66 patients with HCC who underwent surgical treatment. Tumor peak standard uptake value (SUV) was divided by the mean liver SUV (T/LSUV). The mean tumor Hounsfield unit (HU) to mean liver HU was calculated for arterial (T/LHU-A) and portal phases (T/LHU-P). All patients were divided into three groups: I, T/LHU-A ≤l and T/LHU-P <1; II, T/LHU-A >1 and T/LHU-P <1; and III, T/LHU-A >1 and T/LHU-P ≥1. The relationships between the CT perfusion groups and T/LSUV were assessed. Multivariate logistic regression analyses were performed using clinical and imaging parameters for predicting histological grade. Overall survival curves stratified by T/LSUV and CT perfusion groups were estimated using the Kaplan-Meier method.Statistically significant differences in T/LSUV were noted between groups I and II (2.29 [range 1.74-3.60] vs. 1.20 [range 1.07-1.58], P < 0.001) and groups I and III (2.29 [range 1.74-3.60] vs. 1.30 [range 1.07-1.43], P < 0.001). In multivariate analysis, a T/LSUV cutoff of >1.46 was the only independent predictor of tumor grade, with an odds ratio of 8.462 (95% confidence interval 1.799-39.803). Kaplan-Meier curves showed significant differences in OS according to T/LSUV >1.62, group I perfusion pattern, and T/LSUV >1.62 plus group I perfusion pattern (P = 0.04, P = 0.021, and P = 0.002, respectively).18F-FDG PET/CT is not commonly used for detecting HCC due to its limited sensitivity. We found that increased 18F-FDG uptake is associated with decreased arterial and portal perfusion on MDCT. This can be used to preselect patients who would benefit the most from PET/CT. Meanwhile, 18F-FDG uptake remained as the only independent predictor of histological grade, and higher 18F-FDG uptake and lower perfusion pattern on MDCT were significantly related to shorter OS.
Interpreting the febrile neutropenia rates from randomized controlled trials for consideration of primary prophylaxis in the real world: A systematic review and meta-analysis.
Authors: Judy Truong, Esther Lee, Maureen E. Trudeau, Kelvin K. Chan
Journal: Journal of Clinical Oncology (2015)

9626 Background: Guidelines recommend primary prophylaxis (PP) with granulocyte colony stimulating factors (G-CSF) for patients above a febrile neutropenia (FN) risk threshold of 20%. When considering the role of PP with G-CSF, practitioners often use FN rates of regimens based on data from randomized controlled trials (RCTs), which are often comprised of highly selected patients. Patients who received these regimens in the real world may be at higher risk of FN. Methods: A systematic literature search was conducted using MEDLINE, EMBASE, and CENTRAL databases for full-length articles reporting FN rates for breast cancer-related chemotherapies between Jan/96 and Feb/14. A regimen was included if there was at least 1 RCT and 1 observational study (ObS). Any pilot, dose-finding, feasibility, phase I, or phase II studies were excluded. Meta-regression using logistic regression with fixed-effects and random-effects was used to model the odds ratio (OR) of FN with 95% confidence intervals (CI). Results: 128 studies involving 29 regimens and 50,069 patients were identified. 65 ObS (n = 7,812) and 110 RCT (n = 42,257) cohorts were included. The unadjusted FN rate was 11.7% in ObS and 7.9% in RCT cohorts. The univariable fixed effects OR for FN in the ObS compared to RCT cohorts was 1.58 (CI: 1.09-2.28; p= 0.017). The FN rates remained significantly higher in the ObS compared to RCT cohorts (OR = 1.74; CI: 1.15-2.62; p =0.012) in the multivariable mixed effects model adjusted for age, chemotherapy intent, chemotherapy regimen and accounted for random effects of study and chemotherapy regimen. This meant that a 13% FN rate in RCT would translate into 20% FN rate in ObS study. The unadjusted FN rates were higher in taxane regimens than non-taxane regimens in both the ObS (16.5% vs. 6.4%) and RCT (10.0% vs. 4.7%) cohorts. Conclusions: FN rates in ObS are significantly higher than suggested by RCTs in many breast cancer-related chemotherapy regimens. A 13% FN rate in RCT appeared to correspond to the 20% FN rates in the real world. Large population-based studies are needed to confirm FN rates of different regimens in the real world to ensure optimal utilization of G-CSF.
The Clearer BENEFITS of Belatacept
Authors: Eliot Heher, James F. Markmann
Journal: New England Journal of Medicine (2016)

“In the long run,” the economist John Maynard Keynes wryly observed in his 1923 A Tract on Monetary Reform, “we are all dead.” Given the logistic barriers to performing long-term studies of immunosuppression in kidney-transplant recipients, as well as the associated expense, many transplant professionals are similarly pessimistic about how to determine adequate long-term regimens in the current era, in which short-term results are excellent but late transplant loss remains a vexing problem. More than 14,000 of the 101,000 patients listed for kidney transplantation are awaiting repeat transplantation.1 Mechanisms of late transplant loss remain under investigation; toxic effects of . . .
Is Osteoid Osteoma an Iodophilic Lesion?
Authors: Irina Rachinsky, Ilan Shelef, Svetlana Agranovich, Sophie Lantsberg
Journal: Clinical Nuclear Medicine (2003)

The authors present a case of pathologically proved osteoid osteoma that was visualized randomly on an I-131 whole-body scan. Search of the medical literature did not reveal any mention of radioactive iodine uptake by osteoid osteomas. Therefore, the authors concluded that this pathology must be included in the differential diagnostic list of positive findings on I-131 scans.
Gene Therapy for ADA Takes Next Step
Authors: Susan Jenks
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Gene Therapy for ADA Takes Next Step Get access Susan Jenks Susan Jenks Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 6, 18 March 1992, Page 382, https://doi.org/10.1093/jnci/84.6.382 Published: 18 March 1992
99mTc MAG3 Renography Demonstrating Return to Normal Renal Function Following Resolution of Renal Vein Thrombosis
Authors: Jessica R. Leschied, Ka Kit Wong, Milton D. Gross
Journal: Clinical Nuclear Medicine (2012)

Renal vein thrombosis is an uncommon, vascular disorder presenting acutely in adults with flank pain and hematuria. Venography is the imaging standard for diagnosis, although it is usually preceded by noninvasive imaging studies, such as CTA, MRA, Doppler ultrasound, and renal scintigraphy. We present an interesting image case of acute, unilateral renal vein thrombosis in a woman with a history of thromboembolic disease in whom serial 99mTc MAG3 renography demonstrated return to normal renal function after definitive treatment.
The use of Endoscopic Ultrasound as a staging investigation for Oesophago-Gastric cancer reduces the rate of R2 resections and open and close laparotomy
Authors: N Jennings, J Sultan, K Wynne, D Karat, N Hayes, SM Griffin, DL Richardson, SR Preston
Journal: Endoscopy (2006)

To evaluate the effect of endoscopic ultrasound (EUS) in the staging of oesophago-gastric cancer patients, in terms of the proportion of patients that subsequently underwent an open and close laparotomy or R2 resection.
1307 HIGH LEVELS OF URSODEOXYCHOLIC ACID ACT AS FXR ANTAGONIST AND DEPLETE LIVER CHOLESTEROL DUE TO INCREASED BILE ACID SYNTHESIS IN MORBIDLY OBESE PATIENTS
Authors: H.-U. Marschall, M. Mueller, M. Wagner, P. Fickert, G. Zollner, D. Silbert, C. Lackner, A. Thorell, M. Trauner
Journal: Journal of Hepatology (2012)
Protective role of syndecan-4 in experimental colitis
Authors: A Stratis, D Bettenworth, K Neugebauer, M Fröhling, P Paruzel, B Dankbar, None Wemeyer, C Cromme, L Godmann, J Bertrand, A Korb, F Echtermeyer, G Kollias, A Lügering, T Pap
Journal: Annals of the Rheumatic Diseases (2012)

<h3>Background</h3> Syndecan-4 (sdc4) is a transmembrane heparan sulfate proteoglycan that in addition to functioning as an adhesion a molecule can bind cytokines and impact on inflammation. Modulation of inflammatory signals by sdc4 may occur either through mere binding of cytokines, in which case sdc4 acts as decoy receptor or through initiation of sdc-dependent signalling following sdc4 complex formation. While arthritic cartilage damage is decreased in sdc4-deficient mice most likely due to reduced sdc4 signaling, osteopontin- mediated liver damage has been shown to be increased in these mice due to the lack of scd4 decoy receptor function. Based on this dual and in part opposing effects of sdc4, the aim of this study was to investigate if the loss of sdc4 changes the natural course of murine experimental colitis. <h3>Methods</h3> Experimental Colitis was induced in sdc4<sup>-/-</sup> mice and in C57BL/6 WT mice by DSS. The course of colitis was monitored by weight loss as well as assessment of colon length and blinded histological scoring of colonic changes at the end of the experiment. In addition, sdc4<sup>-/-</sup> and C57BL/6 WT mice were orally gavaged with 5×10<sup>8</sup> colony-forming units (CFU) of <i>Citrobacter rodentium</i>. Fecal excretion of <i>C rodentium</i> and changes of body weight were monitored. At day 21 postinfection, inflammatory changes of the colon were evaluated histologically. <h3>Results</h3> Beginning from day 5 after start of DSS-administration, sdc4<sup>-/-</sup> mice lost dramatically more body weight compared to WT animals (day 8: 24.8%±1.9 vs 9.2%±3.1; p=0.008). In accordance with the increased loss of body weight, the colon length of sdc4<sup>-/-</sup> mice was significantly shortened (63.3 mm±2.4 vs 74.8±2.3; p=0.01) and the histological damage according to the Dieleman-Score was markedly aggravated (16AU±3.7 vs 3.4AU±0.2; p=0.016). At day 19 postinfection, the fecal excretion of <i>C rodentium</i> in sdc4<sup>-/-</sup> was prolonged compared to WT animals (2.5×105±6.8×103 vs 9.6×103±6.5×102; p=0.01). Histological damage of colonic mucosa, reflected by lengthening of crypts, was increased in Sdc4<sup>-/-</sup> mice (14.3AU±1.3 vs 10.2AU±0.9; p=0.03). <h3>Conclusions</h3> The data suggest that like in inflammatory liver damage, sdc4 exerts protective effects in intestinal inflammation. Future studies are needed to explore the underlying mechanisms and to determine if these effects are due to a decoy receptor function of sdc4 or whether sdc4 complex formation and signalling is involved.
529 WEEK 12 HBSAG TITER DECLINE IS PREDICTIVE OF SVR IN CHRONIC HEPATITIS B PATIENTS RECEIVING PEGYLATED INTERFERON PLUS TENOFOVIR COMBINATION THERAPY
Authors: P. Marcellin, M. Martinot-Peignoux, M. Lapalus, O. Lada, Q. Zhang, N. Boyer, T. Asselah
Journal: Journal of Hepatology (2012)